1 Westmount Square, Suite 800
Montreal, Quebec
H3Z 2P9
Canada

T 514-849-7696
F 514-849-5191
info@amorchem.com


2017

January 11, 2017
AMORCHEM SPINS OUT ITS SEMAPHORIN 3A TECHNOLOGY INTO SEMATHERA, WITH 1M$ SEED INVESTMENT
   
January 9, 2017
AMORCHEM SPINS USP15-DUB NEUROINFLAMMATION PROGRAM INTO CORBIN THERAPEUTICS

 

2016

November 22, 2016
AmorChem Sells Cystic Fibrosis Assets to Vertex Pharmaceuticals
   
September 12, 2016
AMORCHEM SPINS OUT ITS CD36 TECHNOLOGY INTO MPERIA THERAPEUTICS, WITH 1M$ SERIES A INVESTMENT
   
June 10, 2016
Dr. ANNE-MARIE MES-MASSON: CHAMPION OF THE AMORCHEM KNOCK OUT AND WINNER OF $500,000!
   
May 27, 2016
AmorChem's KNOCK OUT Event: Where academic Contenders duke it out with industry Heavyweight Champions. Who will be left standing in the ring?

 

2015

June 5, 2015
Dr. FACKSON MWALE: CHAMPION OF THE AMORCHEM KNOCK OUT!
   
June 3, 2015
AmorChem's KNOCK OUT Event: Where academic Contenders duke it out with industry Heavyweight Champions to have a chance to win a $500,000 financing.
   
April 7, 2015
AmorChem invests in projects at the Personalized Cancer ImmunoTherapy Program
   
February 11, 2015
AmorChem invests in a mucoadhesive nanoparticle drug delivery platform
   

 

2014

November 26, 2014
AmorChem launches the project of its first Knock-­‐OutTM winner
   
November 7, 2014
AmorChem finances the development of an orthopedic device
   
August 4, 2014
AmorChem, Université Laval and CHU de Québec collaborate on the development of a treatment for Friedreich's Ataxia
   
July 29, 2014
RNA foci disruption – myotonic dystrophy – Dr. Pascal Chartrand PARTNERED WITH ROCHE
   
July 23, 2014
AmorChem invests in a novel drug for atherosclerosis.
   
June 18, 2014
AmorChem investsin adiabetic macular edema opportunity
   
June 17, 2014
AmorChem aims a ttwo major respiratory diseases with a single CFTR strategy
   
June 3, 2014
AmorChemMakes $1.5MInvestmentto Develop New Diagnostic and Prognostic Tools for Acute Myeloid Leukemia

 

2013

December 17, 2013
AmorChem invests in new DUB target for neuro-inflammation.
   
December 10, 2013
AmorChem invests in a potential therapy for late-stage breast cancer
   
November 18, 2013
AmorChem, Université Laval and CHU de Québec collaborate on the development of a treatment for endometriosis and estrogen-dependent cancers
   
November 3, 2013
AmorChem welcomes Martin Leblanc to its Investment Committee
   
October 28, 2013
BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis
   
October 2, 2013
AmorChem's KNOCK-OUTTM Event: We have a Champion!
   
September 19, 2013
AmorChem invests in the development of a therapeutic to treat myotonic dystrophy.
   
September 18, 2013
AmorChem's KNOCK-OUTTM Event: Where academic Contenders duke it out with industry Heavyweight Champions. Who will be left standing in the ring?
   
August 29, 2013
You can knock-out a gene, but can you win the match? Come and find out at the AmorChem KNOCK-OUTTM Event at BioContact 2013 and you could qualify for an AmorChem financing!
   
August 2, 2013
You can knock-out a gene, but can you win the match? Come and find out at the AmorChem KNOCK-OUTTM Event at BioContact 2013 and you could qualify for an AmorChem financing!
   
July 12, 2013
AmorChem invests in a project for the treatment of pulmonary arterial hypertension.
   
May 21, 2013
AmorChem and Univalor announce the success of the first phase of their collaboration with Dr. Nabil Seidah
   
May 7, 2013
AmorChem and InflammatoRx to collaborate on the development of drugs to treat inflammatory and auto-immune diseases
   
April 18, 2013
AmorChem and Univalor team up with Dr. Marc Prentki to discover new drugs against diabetes.
   
February 22, 2013
Dr. Bernard Coupal joins the Investment Committee of AmorChem
   
February 11, 2013
AmorChem invests in epigenetic therapy for the treatment of certain hematological cancers.
   
January 25, 2013
AmorChem invests in the development of 5-oxo-ETE receptor antagonists for inflammation.
   
January 23, 2013
Dr. Kevin McBride joins the AmorChem team.

 

2012

December 21, 2012
AmorChem invests in a novel titanium porous compression screw for bone fixation and puts in place a Master Agreement with McGill
   
November 27, 2012
AmorChem invests in a novel drug for geographic atrophy
   
August 8, 2012
AmorChem invests in a novel cholesterol-lowering biologic product targeting PCSK9 and puts in place a Master Agreement with Univalor
   
April 3, 2012
AmorChem invests in the discovery of a novel cholesterol-lowering drug targeting PCSK9

 

2011

December 5, 2011
AmorChem Financial Inc. launches contract research firm NuChem Therapeutics Inc. and names Dr. John Clement as business development partner
   
About UsProcessPortfolioOur TeamNewsNuChemGeneChemContactFrançais

© 2017 AmorChem. All rights reserved. Developed by Grafika Designs a Montreal Web Design company.